Sign in
CompletedPhase 2

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

Key facts

Who runs it
Radboud University Medical Center
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
10 people enrolled
Started
1 May 2025
Ended
31 Jul 2026
Type of study
Interventional
Treatments tested
  • Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
Record updated
18 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • The patient is at least 18 years old on the day of inclusion
  • The patient has suspected chronic pulmonary aspergillosis or ABPA
  • There is no significant interference with standard care and follow-up

Who cannot take part

  • The patient has been receiving antifungal treatment for more than 48 hours prior to the study day
  • The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receives dialysis
  • The patient is pregnant or planning on becoming pregnant
  • The patient has (chronic) iron overload
  • The patient is not able to lie still in the scanner

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection.

Read full original descriptionShow less

The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like [68Ga]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, [68Ga]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.

The group in the trial

  • InterventionTreatment being tested

    Patients will undergo a PET/CT scan at t=60 min after a single intravenous injection of a fixed dose of 100 MBq +/- 10% \[68Ga\]Ga-DFO-B (gallium-68-deferoxamine) which contains 100 µg deferoxamine (DFO-B).

    Treatment: Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
18 August 2026